Celebrating Women’s Health

It’s National Women’s Health Week, the annual event in which millions of women take steps to improve their health. The week serves as a reminder for women to make health a priority and build positive health habits for life. As we…

Get Tested During STI Awareness Month

Sexually transmitted infections or STIs, also referred to as sexually transmitted diseases or STDs, are common in men and women. April is STD/STI Awareness Month, so there is no time like the present to talk with your sexual partner(s) and get…

“Yes Means Test” During Condom Awareness Month

While February is the month of love, it also serves as Condom Awareness Month, and there’s no better time to remind you to protect yourself and your partner from Sexually Transmitted Infections (STIs) by using condoms. Using condoms every…

Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test

,
Proposed LCD will allow Medicare coverage within criteria for the 4Kscore® Test MIAMI, June 28, 2019 (GLOBE NEWSWIRE) — OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination…

BioReference and GenPath Support Man Cave Health During National Men’s Health Month

Complimentary PSA Testing Provided to Participants of Annual Golf Tournament ELMWOOD PARK, N.J., June 7 – BioReference Laboratories, Inc., along with its specialty oncology and urology division, GenPath, announce today their support of…

Aerobic Vaginitis (AV) Testing Now Available At BioReference and GenPath

National launch of aerobic vaginitis (AV) testing coincides with National Women’s Health Week Elmwood Park, NJ, May 17, 2019 — BioReference Laboratories, Inc., an OPKO Health company, along with its specialty women’s health division,…

BioReference and GenPath to Present at ACOG 2019, Demonstrating Commitment to the Research of Hereditary Conditions

ELMWOOD PARK, N.J., May 2, 2019 – BioReference Laboratories, Inc., an OPKO Health Company, along with its women’s health division GenPath, today announced the presentation of new research from its prenatal and hereditary cancer assessment…